Approval · Notice of Compliance 29446 · 2022
MINT-APREMILAST: Notice of Compliance 29446
Issued November 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29446
- Date
- November 14, 2022
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- OTEZLA (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-APREMILAST | 02525747 | Dormant |
Medicinal ingredients
- APREMILAST 30 MG per TAB